Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Trial Profile

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Axitinib (Primary) ; Bosutinib (Primary) ; Cetuximab (Primary) ; Cobimetinib (Primary) ; Crizotinib (Primary) ; Erlotinib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sunitinib (Primary) ; Temsirolimus (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
  • Indications Cholangiocarcinoma; Gallbladder cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms TAPUR
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Results of cohort of patients with pancreatic cancer and gallbladder or bile duct cancer treated with palbociclib presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 30 May 2018 Planned number of patients changed from 1060 to 1440.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top